Roxithromycin

Chemical formula: C₄₁H₇₆N₂O₁₅  Molecular mass: 837.047 g/mol  PubChem compound: 6915744

Therapeutic indications

Roxithromycin is indicated for:

Tonsillitis

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Tonsillitis and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute pharyngitis

Population group: only children (1 year - 12 years old)

Acute pharyngitis and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute pharyngitis

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Acute pharyngitis and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Sinusitis

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Sinusitis and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Dental infections

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Dental infection and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute bronchitis

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Acute bronchitis and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute exacerbation of chronic bronchitis

Population group: only adults (18 - 65 years old)

Acute exacerbation of chronic bronchitis and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Skin infections

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Infective dermatological disorders and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Community acquired pneumonia

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Community acquired pneumonia and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Non-gonococcal urethritis

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Nongonococcal urethritis and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Αcute tonsillitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Acute tonsillitis and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Impetigo

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Impetigo and additionally at least one of
Roxithromycin susceptible species
Cefuroxime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Roxithromycin is contraindicated in the following cases:

Ergot alkaloids

at least one of
Ergot alkaloids
Ergot alkaloids
Ergot alkaloids

Hypersensitivity to macrolides

Allergy to macrolide

Severely impaired hepatic function

Hepatic failure stage IV

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: ARROW ROXITHROMYCIN Coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈